Specialty chemical manufacturer Epigral Ltd reported a 38% year-on-year decline in consolidated net profit for the quarter ended June, settling at ₹99.74 crore.
Despite the earnings miss, the company signaled continued aggressive growth ambitions, announcing plans to invest ₹600 crore in setting up new production plants in Gujarat.
The profit contraction highlights the ongoing pressure on Indian chemical firms, which have faced margin squeezes and demand volatility in recent quarters.
Epigral’s decision to proceed with significant capital expenditure amid lower profitability suggests management’s confidence in a near-term recovery in specialty chemical demand.
The ₹600 crore investment in Gujarat is expected to expand the company’s manufacturing footprint and potentially improve supply chain efficiency.
The state has emerged as a key hub for chemical manufacturing due to its infrastructure and policy support.